Association of dengue virus-specific polyfunctional T-cell responses with clinical disease severity in acute dengue infection.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
12 2019
Historique:
received: 26 03 2019
revised: 31 07 2019
accepted: 27 08 2019
pubmed: 1 10 2019
medline: 27 3 2020
entrez: 1 10 2019
Statut: ppublish

Résumé

Although the role of dengue virus (DENV)-specific T cells in the pathogenesis of acute dengue infection is emerging, the functionality of virus-specific T cells associated with milder clinical disease has not been well studied. We sought to investigate how the functionality of DENV-NS3 and DENV-NS5 protein-specific T cells differ in patients with dengue fever (DF) and dengue hemorrhagic fever (DHF). Using intracellular cytokine assays, we assessed the production of interferon γ (IFNγ), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein-1β (MIP-1β), and CD107a expression in adult patients with acute DF (n = 21) and DHF (n = 22). Quadruple cytokine-producing, polyfunctional DENV-NS3- and DENV-NS5-specific T cells were more frequent in those with DF when compared to those with DHF. While DENV-NS3- and DENV-NS5-specific T cells in patients with DF expressed IFNγ > TNF-α > MIP-β > CD107a, T cells of those with DHF predominantly expressed CD107a > MIP-1β > IFNγ > TNF-α. Overall production of IFNγ or TNF-α by DENV-NS3- and DENV-NS5-specific T cells was significantly higher in patients with DF. The majority of NS3-specific T cells in patients with DF (78.6%) and DHF (68.9%) were single-cytokine producers; 76.6% of DENV-NS5-specific T cells in those with DF and 77.1% of those with DHF, produced only a single cytokine. However, no significant association was found with polyfunctional T-cell responses and the degree of viraemia. Our results suggest that the functional phenotype of DENV-specific T cells are likely to associate with clinical disease severity.

Identifiants

pubmed: 31568656
doi: 10.1002/iid3.271
pmc: PMC6842812
doi:

Substances chimiques

Cytokines 0
NS3 protein, flavivirus 0
NS5 protein, dengue virus 0
Viral Nonstructural Proteins 0
Serine Endopeptidases EC 3.4.21.-
RNA Helicases EC 3.6.4.13

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

276-285

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137881017
Pays : United Kingdom
Organisme : Medical Research Council
ID : G116/150
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209222/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701693
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12010/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14131
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14103
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00008/5
Pays : United Kingdom

Informations de copyright

© 2019 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

PLoS One. 2012;7(7):e37535
pubmed: 22829867
Immun Inflamm Dis. 2019 Dec;7(4):276-285
pubmed: 31568656
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
J Virol. 2016 Nov 28;90(24):11259-11278
pubmed: 27707928
J Infect Dis. 2011 May 1;203(9):1282-91
pubmed: 21335561
PLoS Pathog. 2013;9(7):e1003504
pubmed: 23874205
Am J Respir Crit Care Med. 2016 Jan 1;193(1):78-85
pubmed: 26372850
BMC Infect Dis. 2016 Jul 08;16:319
pubmed: 27391896
Front Immunol. 2018 Feb 16;9:276
pubmed: 29503649
PLoS Negl Trop Dis. 2018 Oct 1;12(10):e0006540
pubmed: 30273352
J Virol. 2005 May;79(9):5665-75
pubmed: 15827181
Methods Mol Biol. 2019;1911:349-361
pubmed: 30593638
PLoS Negl Trop Dis. 2013 Sep 05;7(9):e2409
pubmed: 24040431
Vaccine. 2019 Aug 14;37(35):4848-4849
pubmed: 30424888
J Virol. 2015 Jan;89(1):120-8
pubmed: 25320311
Exp Mol Med. 2017 Sep 29;49(9):e382
pubmed: 28960213
Clin Vaccine Immunol. 2007 Aug;14(8):969-77
pubmed: 17567768
J Clin Invest. 2008 Mar;118(3):1143-53
pubmed: 18246203
J Infect Dis. 2015 Nov 15;212(10):1618-28
pubmed: 25943203
Immunology. 2005 Jun;115(2):239-45
pubmed: 15885130
J Exp Med. 2004 Apr 5;199(7):925-36
pubmed: 15051762
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
Hum Vaccin Immunother. 2012 Sep;8(9):1259-71
pubmed: 22894958
PLoS Negl Trop Dis. 2015 Apr 13;9(4):e0003673
pubmed: 25875020
Cell Immunol. 2009;254(2):149-54
pubmed: 18835598
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7578-E7586
pubmed: 30038008
J Infect Dis. 2015 Dec 1;212(11):1743-51
pubmed: 25980035
Hum Vaccin Immunother. 2018;14(9):2158-2162
pubmed: 29482433
J Infect Dis. 2007 Jun 15;195(12):1799-807
pubmed: 17492596
J Virol. 2002 Feb;76(3):1071-6
pubmed: 11773383
Clin Diagn Lab Immunol. 1998 Jan;5(1):7-10
pubmed: 9455871
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2311
pubmed: 23875046
PLoS One. 2012;7(11):e50387
pubmed: 23209731
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Nat Med. 2003 Jul;9(7):921-7
pubmed: 12808447
FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):33-42
pubmed: 12589955
J Immunol. 2006 Mar 15;176(6):3821-9
pubmed: 16517753
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4256-63
pubmed: 26195744
Sci Transl Med. 2015 Mar 11;7(278):278ra35
pubmed: 25761891
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53
pubmed: 23580623
Immunol Rev. 2008 Oct;225:300-13
pubmed: 18837790
Methods Mol Biol. 2018;1808:173-179
pubmed: 29956183
PLoS One. 2007 Dec 05;2(12):e1192
pubmed: 18060049
J Virol. 2009 Jun;83(11):5514-24
pubmed: 19297503

Auteurs

Dulharie T Wijeratne (DT)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Samitha Fernando (S)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Laksiri Gomes (L)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Chandima Jeewandara (C)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Geethal Jayarathna (G)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Yashoda Perera (Y)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Samurdhi Wickramanayake (S)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Ananda Wijewickrama (A)

Infectious Diseases Hospital, Angoda, Sri Lanka.

Graham S Ogg (GS)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre and University of Oxford, Oxford, UK.

Gathsaurie N Malavige (GN)

Centre for Dengue Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre and University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH